leukopaks (Charles River Laboratories)
86
Structured Review
Charles River Laboratories
leukopaks
Leukopaks, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/leukopaks/leukopaks/pm40795576-47-0-1
Average 86 stars, based on 1 article reviews
Leukopaks, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/leukopaks/leukopaks/pm40795576-47-0-1
Average 86 stars, based on 1 article reviews
leukopaks - by Bioz Stars,
2026-10
86/100 stars
Images
Related Articles
other:Article Title: Label-free chimeric antigen receptor T-cell expression analysis using neural networks and statistical distribution modeling. Article Snippet: Chimeric antigen receptor T (CAR-T)-cell therapy has emerged as a promising treatment for hematologic malignancies.. Accurate monitoring of CAR expression levels is essential for optimizing therapeutic efficacy and ensuring patient safety.. Conventional assessments rely on antibody-based flow cytometry (FCM)—a laborintensive process that may alter cellular properties. Article Title: Evaluating CAR T cell therapy processing with the Sefia™ expansion system using commercially available cell culture media Article Snippet: s / Cytotherapy 27 (2025) S9 S243 S173 therapy for cortical T-ALL, currently in a Phase I clinical trial (NCT05679895).. However, CD1a CAR-T only covers about 30% of all T-ALL cases.. Here, we propose CCR9 as a safe target for T-ALL used in combination with CD1a as a new dual CAR-T treatment of phenotypically heterogeneous T-ALL cases. Article Title: CRISPR-Cas9 engineering of human T regulatory cells - Design and optimization of a manufacturing process. Article Snippet: Leukapheresis products ( Derivative Assay:Article Title: Multi-targeted, NOT gated CAR-T cells as a strategy to protect normal lineages for blood cancer therapy. Article Snippet: PBMCs were obtained from STEMCELL. .. Enriched Article Title: Multi-targeted, NOT gated CAR-T cells as a strategy to protect normal lineages for blood cancer therapy Article Snippet: PBMCs were obtained from STEMCELL. .. Enriched Isolation:Article Title: Automated Vertical Wheel Bioreactor Integrated with Process Analytics for T Cell Manufacturing Article Snippet: Biomanufacturing of cell therapies involves highly complex and labor-intensive processes, where the process parameters and biological variabilities can significantly influence product quality, reproducibility, and therapeutic efficacy.. Here, we developed a vertical wheel-based bioreactor platform with automated controls and in-line process analytical technologies (PAT) to demonstrate successful closed-system T cell biomanufacturing.. By identifying the critical process parameters (CPP), a process development strategy was optimized for expanding primary human unmodified and chimeric antigen receptor (CAR) T cells using multiple activation systems, including degradable micro scaffolds (DMS). |